Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MITF | O75030 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22323092 | 0.98 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2AACHELMNA | |
| SCHEMBL22322972 | 0.88 | ALDH1A1 (0.54) | ALDH1A1MAPTKMT2AACHELMNA | |
| SCHEMBL9911024 | 0.84 | ALDH1A1 (0.54) | ALDH1A1KMT2AMITFSMN1; SMN2ATM | |
| SCHEMBL12284224 | 0.84 | SMN1; SMN2 (0.65) | ALDH1A1MAPTKMT2ALMNAMITF | |
| SCHEMBL8343572 | 0.84 | HTR1A (0.56) | KMT2AMEN1 | |
| SCHEMBL22323042 | 0.83 | ALDH1A1 (0.62) | ALDH1A1MAPTKMT2AACHELMNA | |
| SCHEMBL6265297 | 0.82 | LMNA (0.48) | ALDH1A1MAPTLMNASMN1; SMN2ATM | |
| SCHEMBL13342873 | 0.80 | HTR1A (0.62) | ALDH1A1ACHE | |
| SCHEMBL13343050 | 0.80 | HTR1A (0.62) | ALDH1A1ACHE | |
| SCHEMBL1520775 | 0.80 | HTR1A (0.62) | ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | BAYER AKTIENGESELLSCHAFT (DE) | 2025-02-18 | — | — | US | disclosed |
| EP-3921317-B1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AG (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3921317-B1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AG (DE) | 2023-08-02 | — | — | EP | disclosed |
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-16 | — | — | US | disclosed |
| EP-3921317-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020161257-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020161257-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-13 | — | — | WO | disclosed |
| CN-104011043-B | The quinuclidine esters of 1-aza heterocycles guanidine-acetic acid, their preparation method and Pharmaceutical composition thereof as muscarine antagonist | 奇斯药制品公司 | 2016-11-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046077-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | CSNK1A1, CSNK1G1, CSNK1E | ALDH1A1 2154/4885MAPT 2232/4885KMT2A 1912/4885 |
| US-12227501-B2 | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as CSNK1 inhibitors | CSNK1A1, CSNK1G1, CSNK1E | ALDH1A1 2154/4885MAPT 2232/4885KMT2A 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.